Curi Bio Names Nicholas A. Geisse, Ph.D., as New Chief Executive Officer
Read More
Curi Bio is proud to announce that Co-founder and Chief Business Officer Elliot Fisher has been listed as one of Forbes 30 Under 30 in healthcare.
In this 12th annual 30 Under 30 list, Forbes recognizes a set of tomorrow’s brightest young professionals in 20 separate categories, each of which showcase how the leaders are boldly tackling the problems of today.
Read More
Curi Bio Launches Mantarray™ Platform, 3D Engineered Muscle Tissues for Discovery of New Therapeutics
Read More![[Webinar Replay] A Scalable System to Engineer Human 3D Muscle Tissues for Drug Discovery](https://images.squarespace-cdn.com/content/v1/5ea9dcad38347f7b8405d2f9/1657230079077-3JXIS2LWSMQP6RUCVO2E/Mantarray-Webinar-2022-Curi-Bio_website-01.png)
![[December 2021 Newsletter] Calcium Flux Detection in Engineered Muscle Tissues](https://images.squarespace-cdn.com/content/v1/5ea9dcad38347f7b8405d2f9/1641233693933-YD4C1OG4CB1K0UAPZY46/holiday-2021-01.jpg)
![[Webinar Replay] Mantarray: Scalable Human-relevant 3D-Engineered Cardiac and Skeletal Muscle Tissues for Safety and Efficacy Studies](https://images.squarespace-cdn.com/content/v1/5ea9dcad38347f7b8405d2f9/1635451504361-668M1WCZ7B10BCX0LLZG/top-load-hero-blue-bg.gif)
![[October 2021 Newsletter] Live Webinar: Sign up now to secure your spot!](https://images.squarespace-cdn.com/content/v1/5ea9dcad38347f7b8405d2f9/1634329570429-G5T9TUBC2FB885M78TTE/Mantarray-Webinar-2021-Curi-Bio-01.png)
![[September 2021 Newsletter] Curi News – Mantarray Detection of Drug-induced Contractile Changes](https://images.squarespace-cdn.com/content/v1/5ea9dcad38347f7b8405d2f9/1634069219121-QZVRUTU9WQJE5PHWBX55/CuriBio_Mantarray-Dox-Graphs-02.jpg)
On May 13, 2021, Curi Bio’s CSO, Dr. Nicholas Geisse, was a panelist for Device Connect by Life Science Washington hosted by Product Creation Studio. We wanted to share the great discussion here for anyone who missed. Enjoy!
Read More
The Mantarray platform was announced among the finalists within the AI and Data category of Fast Company’s World Changing Ideas Awards 2021. The Mantarray enables the discovery, safety, and efficacy testing of new therapeutics by providing parallel analysis of 3D engineered muscle tissues with adult-like functional profiles, bringing clinically-relevant functional data into the earliest stages of preclinical testing of new medicines.
Read More
SEATTLE – Curi Bio, Inc. announced today that their Mantarray™ platform won a Bronze Edison Award. Named after Thomas Alva Edison, the Edison Awards have recognized and honored some of the most innovative new products, services, and business leaders in the world since 1987.
Read More
Curi Bio Inc., a leading developer of human stem cell-based platforms for drug discovery, announced today it has raised $6 million in a Series A financing round.
Read More
Curi Bio is honored to be announced a 2020 Tibbetts Award Winner by the U.S. Small Business Administration! This award recognizes our critical role in successfully driving high-tech innovation within the U.S. with our next-generation human stem cell platforms. #sbirTibbetts
Read More